Sign Out
Pregnancy: There is a limited amount of data (less than 300 pregnancy outcomes) from the use of lanreotide in pregnant women.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of lanreotide during pregnancy.
Breast-feeding: It is not known whether Somatuline Autogel is excreted in human milk.
A risk to the newborns/infants cannot be excluded.
Somatuline Autogel should not be used during breast-feeding.
Fertility: Reduced fertility was observed in female rats due to the inhibition of GH secretion at doses in excess of those achieved in humans at therapeutic doses.
